Default company panoramic image

Paradise Genomics

Paradise discovers proprietary biomarkers in blood for the early detection of cancer as well as diagnostic test and drug development targets

  • Stage Concept Only
  • Industry Not Set
  • Location Libertyville, IL, USA
  • Currency USD

Company Summary

Paradise Genomics focuses on the discovery of dynamic biomarker signatures with significant advantages in cost, discovery rate, and sensitivity. These proprietary disease signatures will be marketed for commercialization to strategic partners with established product and distribution systems. Marketing partners will primarily be pharmaceutical, biotechnology, and medical diagnostic companies. Paradise Genomics will focus on a disease portfolio t


  • Default avatar
    Scott Magnusson
    PhD, Co- Founder, Chief Scientific Officer

    -Responsible for directing product development efforts, expanding product and service capabilities, and looking for new genomics-based areas of expansion.
    -Dr. Magnuson previously was Head of Gene Expression, Genomics, and Bioinformatics at Amersham following the acquisition of Motorola Life Sciences.
    -At Motorola, Dr. Magnuson, was instrumental in the development of the CodeLink microarray products (currently acquired by Applied Microarrays